ADXS Advaxis Inc

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * SIDRANSKY DAVID	2. Issuer Name and Ticker or Trading Symbol Ayala Pharmaceuticals, Inc. [ ADXS ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) 9 DEER PARK DRIVE, SUITE K-1	3. Date of Earliest Transaction (MM/DD/YYYY) 1/19/2023
(Street) MONMOUTH JUNCTION, NJ 08852 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	1/19/2023		A		46	A	(1)	46	I	Held by Reporting Person's Son
Common Stock								93	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$55.23	1/19/2023		A		2342		(2)	6/9/2031	Common Stock	2342	(3)	2342	D
Stock Option	$8.70	1/19/2023		A		2342		(4)	6/12/2032	Common Stock	2342	(5)	2342	D
Stock Option	$16128							(2)	5/27/2025	Common Stock	17		17	D
Stock Option	$15372							(2)	11/4/2025	Common Stock	42		42	D
Stock Option	$9252							(2)	11/3/2026	Common Stock	25		25	D
Stock Option	$3828							(2)	11/1/2027	Common Stock	25		25	D
Stock Option	$648							(2)	11/4/2028	Common Stock	25		25	D
Stock Option	$24.80							(2)	10/23/2029	Common Stock	125		125	D
Stock Option	$52.80							(6)	5/3/2030	Common Stock	163		163	D

Explanation of Responses:
(1)	Received in exchange for 250 shares of the common stock of Ayala Pharmaceuticals, Inc. ("Old Ayala") in the merger of Old Ayala into the Issuer (the "Merger"). On the day prior to the effective date of the Merger, the closing price of Old Ayala's common stock was $0.53 per share, and the closing price of the Issuer's common stock was $2.95 per share.
(2)	This option is fully vested and exercisable.
(3)	Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $10.35 per share.
(4)	This option vests and becomes exercisable on the earlier of (i) June 13, 2023 or (ii) one day prior to the Issuer's 2023 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer through such vesting date.
(5)	Received in the Merger in exchange for an employee stock option to acquire 12,500 shares of the common stock of Old Ayala for $1.63 per share.
(6)	Two-thirds of this award is currently vested and the remaining one-third will be vested on May 4, 2023.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SIDRANSKY DAVID 9 DEER PARK DRIVE, SUITE K-1 MONMOUTH JUNCTION, NJ 08852	X

Signatures
/s/ David Sidransky		1/23/2023
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.